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'FHl2.J L'lO.LB OF ALDOSTERONE

Lli

TIHl!.;

.PATHOGJ:!jl\l.t:.;0It) OF

H.YJ:J1~RT'J:'jN/:::lIOH

The high incidence and vast importance of high
blood pressure in the causation of disease and death
today are unquestioned.

Hypertension is second only

to arteriosclerosis as the disease with the greatest
fatality rate, and accounts for over one-fifth of
all deaths per year.

(1)

The exact incidence of hypertension as quoted
by different investigators varies greatly.

It has

been variously computed as twenty million, fifteen
million, and six million persons in the United states
alone.

This discrepancy is not due to error, but to

varying criteria used in the selection of cases.
Hypertension, either primary or secondary, occurs in
five to twenty per cent of the total population, and
its incidence rises to over fifty per cent in persons over age fifty.
The term hypertension connotes a systemic arterial pressure consistently above the accepted normal
values.

These are customarily established as 140/90.

However, many people today regard fixed criteria for
diagnosis as no longer acceptable.
1

True hypertension

implies an elevation in both systolic and diastolic
blood pressures.

Although it is possible for only

the systolic pressure to be elevated, this systolic
type of hypertension is etiologically distinct, and
is a field separate from the realm of this thesis.
Here only the true or diastolic hypertension will
be considered.
Hypertension has been variously classified by
different investigators.

Perhaps the most standard

one is the classification

w~~ch

is reproduced below.

Etiologic Classification of Hypertension
I.

II.

Essential

(or Primary)

A.

K
.
.uenlgn

B.

Malignant

(incidence about ninety per cent)
(incidence about ten per cent)

Secondary

A.

Renal

B.

Endocrine

C.Neurogenic

D.

Psychogenic

E.

Cardiovascular

F.

Miscellaneous

When there is a persistent elevation of the systolic
and diastolic blood pressures without a demonstrable
cause, the condition is referred to as essential or
2

primary hypertension.

This is subdivided into the

benign or chronic phase, and the malignant or accelerated phase, depending on the rate of progression
of the disease.

Benign hypertension is character-

ized by a gradual and often insidious onset, slow
progression, and long duration extending over ten
to forty years.

Malignant hypertension refers to

the small per cent of cases (one to seven per cent)
which progress rapidly and are characterized by high
diastolic blood pressure, papilledema, progressive
renal failure, and renal necrotizing arteriolitis
at autopsy.

(2)

Some workers feel that this clas-

sification is incorrect, as they feel secondary
hypertension may enter a malignant Dhase.

This

argument is beyond the scope of this thesis.
It has been the goal of many investi

ors

througb the years to discover a morphological or
biochemical abnormality which 'would act as a causative factor to expla

the hypertensive phenomena

now classified as es,sential hypertension.

h

increased knowledge of endocrinology, including the
isolation, purification, and synthesis of adrenal
cortical hormones, many vvorkers feel this is now
possible.

To investigate this possibility, this

thesis is dedicated.

3

In

1952, Simpson and Tait (3) first showed that

it was a new steroid which was responsible for tbe
1 corticoid activity of the adrenals.

Two

years later, these same workers, in collaboration
with Heichste

, Wettstein, and their respective

EsT-OUPS, discovered its chemical formula.

This ITI.in-

eral corticoid was later named aldosterone.

The chemical formula of aldosterone shows the
important differentiat

point between t

s hormone

Find cortiscne, hydrocortj.soDe, ane other steroids.
(4)

This is the "presence of an aldehyde

position eighteen.

in

In solution, aldosterone is mainly

in the form of a hemiacetal between C eleven and C
eighteen, as shown above.
4

Aldosterone is the major mineral corticoid
excreted by the adrenal cortex, but is not the only
one.

II-Desoxycorticosterone and dehydroepiandosterone

are also mineral corticoids but hav2

leE3s IJ.orma.l

siological activity than does aldosterone.

Com-

parative bioassays have revealed that adrenal steroids
may not act purely as gluco or mineral corticoids,
but may have overlapping functional potencies.

rrhe

co.mparative act jon of aldosterone, hydrocortisone,
and desoxycorticosterone are listed below.

HORl'V101~E

.0f:./I' I1'vJ.i1il1b D
GlJUOOCOldlICOID

:::rydrocortisone
Aldosterone
DOC (Desoxycorticosterone)

(5)

OBrICOID

1

1

0.5

200-400

0

25

The functional zonation of the adrenal cortex
has been established beyond any reasonable doubt.
(6)

The zona glomerulosa produces mostly mineral

corticoids and is little affected b
whereas the zona fasciculata
form predominately

~luco

an~

corticotropin,

zona reticularis

corticoids, 17-keto ster-

oids, and estrogens, and are dependent upon corticotropin for growth and secretory

5

st~mulation.

Aldosterone is synthesized mainly by the enzymatic introduction. of an aldehyde group in the C
eighteen methyl group in the d position.

.Smaller

amounts of aldosterone are synthesized tltrough other
hways.

Only the d form is biologically active.

e is only very minimal binding in the plasma,
and this is to albuIILin.
The control of the secretion of aldosterone has
not been completely elucidated.

Several factors have

been recognized as causing an increase in aldosterone
secretion.
1.

(6)
Reduction in intravasclJlar volume

This reduction in intravascular volume as it occurs
after sodium restriction, dehydration, or

sma

extravasation causes the greatest increase in secretion--ten to forty-fold above normal.

Converse

overhydration with sodium chloride intakes of greater
than

5

grams per day, or infusion of blood or albumin

lead to a decrease in normal aldosterone secretion.
Various baroreceptors in the carotid arteries and
the right atrium have been implicated in the regulatioIl of these volume-induced changes, but these
have not been proven.
6

2.

Angiotension II

Angi_otension II, the active
renin

COl!J. ponent

formed in

may cause an increase in aldosterone secre-

tion.

3.

Adrenoglomerulotropin

Adrenoglomerulotropin, a lipid factor extracted
from the pineal gland, may increase

a~dosterone

secretion.
4.

Adrenocorticotropic hormone

Pituitary corticotropin does increase aldosterone
the rise is smaller than

secretion in man,

that sustained by other adrenal ster6ids, and is not
prolonged.
rrl'1e plJ.ysiologic

ortance and effect of aldo-

sterone in man was not realized until 1955 when Conn
described the

~:;~1Ddrome

oJ a pota,sf3ilJJu los

tis which he called primary aldosteronism.
is now known as Conn's syndrome.

;;; nephri(7)

This

Clinically, this

syndrome is characterized by paresthesias, intermittent tetany, Dolyuria, polydipsia, severe periodic
':Ne

ss and Hparalyses ll

a lack of edema.

arterial hypertension, and

,

The biochemical laboratory data in

such cases show an alkalosis with a pH greater than

7.5, a lovv serum potassium (1.6-2.5 mEq. jL), and a
7

high serum sodium.

The sweat, salivary, and urinary

potassium values are
sodium are high.

lo~

whereas t

se values for

Pathologically there is usually

an adrenocortical tumor (adenoma), or distinct
adrenocortical hyperplasia.
With the discovery of aldosterone and the identification of Conn's syndrome, it was not long until
investigators were postulating the possible causation of cases of essential hypertension via the aldosterone mechanism.

rrhere were many presumptive

evidences at that time which might have le d

investi-

gators to such a hypothesis.

Presumptive Evidences for this Helationship
Such a hypothesis (that essential hypertension
was caused by an excess production of aldosterone)
could explain many already known clin:Lcal and exper:Lmental observat:Lons.
1.

The hypertension in Cushing's syndrome
and the hypotension in Addison's disease.

2.

The hypertension in the s:)rndrome of primary

3.

aldosteronis~.

(Conn's syndrome)

The correlation between the elevation of
8

blood pressure in patients, and their
sodium chloride intake.
4.

(8)

The benefical effect in a certain number
of hypertensive patients of the rice diet

(9, 10, 11) or diets limited to two hundred and fifty mg. of sodium per day_
(12, 13, 14)

5.

The increased concentration of sodium in
the muscles and arteries of patients with
essentj_al hypertension, and of animals
made hypertensive by various procedures.
(15, 16)

6.

The hypertensive effect of desoxycorticosterone acetate in normal subjects and
in Addisonians receiving a diet with normal
amounts of sodium.

(17, 18, 19, 20)

The

potentiating effect of salt on this DOCA
pressor activity, (21, 22) and the disappearance of this effect when sodium.
chloride is removed from the diet.

7.

(22)

The increase in the DOCA pressor effect
in animals with decreased renal functional
mass.

(23)

9

8.

The DOCA pressor effect in nephritic
and hypertensive patients.

9.

(17, 24)

The rise in blood pressure after an
increase in dietary salt in hypertensive
patients, (22) and the disturbance in
salt and water excretion following sodium
restriction.

10.

(25)

The identical appearance of the capillaries of the bulbar conjunctiva in
patients with essential hypertension and
in patients with Cushing's syndrome.

11.

(26)

The hypertrophy of the adrenal cortex,
especially the zona glomerulosa after
angiotensin administration in experimental
renal hypertension.

12.

(28)

The blood pressure fall in patients with
essential hypertension following restriction of dietary potassium.

13.

(29)

The significant decrease in hypertension
after complete removal of the adrenal cortex in dogs and rats with acute or chronic
.
' 1 h,yper"t;enslon.
'
.
experlmen1Ja_

(An
\../v,

31 , )22')

This evidence is, however, only pre sumpt iv'e •
Before the validity of the hypothesi,s can be tested,
concrete evidence must be obtained.
10

Evidence Substantiating this Hypothesis

The most extensive investigations of the role
of aldosterone have been made by Genest.
work was

be~un

(33).

His

in 1948 when only the most basic work-

ing hypotheses were known, and measurements for separating and measuring adrenocorticosteroids were very
crude.

These first studies used an aluminum oxide

column for eluting the corticosteroid fraction of
urine.

With these methods he could detect no dif-

ference between the values obtained for h;y-pertensive
patients with high sodium

takes and high blood

pressure levels, and these same patients during
sodium restriction with blood pressure reduction to
normotensive levels.
After aldosterone was discovered in 1952 by
Simpson and Tait, using the newest techniques of
paper ch..romatography and the biological assay for
sodium-retaining act ivi ty 'which they sugge sted,
Genest was able to isolate the purified aldosterone fraction. When this fraction of the purified
extract obtained from the urine of hypertensive
patients was then injected into adrenalectomized
11

rats, a significant decrease (p is less than 0.001)
in the urinary sodium potassium ratio could be seen,
in

co~parison

with those rats which received injec-

tions of urine fraction extracts from normotensive
patients.

Thus this finding suggested first, in

1956, that more aldosterone was excreted in the urine
of hypertensive patients than of normotensive ones.
(34)
This method was soon found to lack specificity
and accuracy, and in

1958, Genest reported studies

on tbis problem using a nevv ph;)Tsico-chemical rnetbod
of aldosterone determination.

(35)

demonstrated a two-fold increasE

~

With this he
mean urinary

aldosterone excretion in patients with essential,
renal, and malignant hypertension, as conpared to
normal subjects.

'I'his difference 'Nas statist ically

significant with p less than 0.001.

Also he demon-

strated an excessive daily variation in the aldosterone content of the urine of hypertensive patients.
This was in marked contrast to the relatively stable
excretion of aldosterone in normal subjects.

He could

find no reason to account for these variations--such
as the nresence of acute stress, a chronic anxiety
state, or tbe level of sodium or potassium intake.

12

In 1960 he completed two hundred forty-seven
determinations of urinary aldosterone in one hundred
forty-three normal sub,jects and hypertensive patients
(36)

In this study, patients with essential, renal,

and. malignant hypertension shovved a two-fold to fourfold increase in average urinary aldosterone excretion
as compared to normotensive patients.

Forty-three per

cent of all aldosterone determination

patients with

essential and malignant hypertension were greater tb.an
"
\
the upper normal limit (two to ten micrograms per Gay)
•

In each of the th.ree

grou~s

the differences between

the means were statistically significant.

For essen-

tial hypertension as compared to normotension, p was
less than 0.001.
to normotension,

filor renal hypertensIon as compared
p

was less than 0.005.

For malig-

nant hypertension as compared to normotension, p 'Nas
less than 0.001.
These results are from spot determ
hypertensive patients.

tions on

However, Genest realized that

such determinations could not reflect the marked overlapping which might occur between normal and hypertensive patients.

For this reason he introduced a

continuous study of the urinary aldosterone secretion
of hypertensives and nOrl:Jals for periods of five to
twenty consecutive days.

In some cases the subjects

13

were placed on fixed sodi.um and potassium intake diets.,
while in others, the diets were self-selected.

Normal

subjects' daily urinary aldosterone excretion remained
vvell IJljithin normal limits even when these subjects were
undertaking their usual activities, and despite marked
variations in dietary sodium intake.

However, all of

the hypertensives but one showed excess fluctuation of
daily urinary aldosterone above normal range despite
hospitalization.

These fluctuations were more marked

in the malignant phase of hypertension but were also
:oresent in asymptomatic essential hypertension.

No

edema was present in these subjects.
There are several plausible explanations for the
wide fluctuations of urinary aldosterone nobed.
may be a variation in excretion rate, or an a

s
era-

tion in the metabolic degradation of aldosterone and
its consequent urinary excretion.

Fluctuations may

occur as a result of emotional disturbances.

Increases

have beerJ. obe,erved in medical students during examinations when anxiety was nresent.

(3'7)

A.lso one

should consider the fact that the adrenal glands of
hypertensive patients might be more respon,sive to
adrenocorticotropic hormone.

This possibility may

be considered rather unlikely, due to the fact that
ACTH' is thought by most observers to have only a
slight tropic action on aldosterone.

14

Genest's results wit:1. essential hypertension
were confirmed by Garst.

(38)

She initiated a

study whose primary aim was to determine the incidence of aldosteronism in ll;rpertensive 1)atients.

In

this statistically well-documented study she found
that about twenty-five per cent of the patients with
essential hypertension had significantly elevated
levels of urinary aldosterone, using a paper chroma1Jography method for determination.

In none of

these patients, however, were the abnormal serum
electrolyte changes seen such as occur in primary
aldosteronism.
Venning (39) studied aldosterone in hypertensives by a similar method with special emphasis on
aldosterone changes as correlated with specific
etiologies.

She found

tha~

although the majority

of the patients vvith essential hypertex1sion on a
normal sodium diet excrete(l amounts of aldosterone
within normal range, the mean value was statistically significantly higher than that seen in normotensive patients.

She noticed also that most of the

hY1)ertensive patients were in an older age than the
normotensive ones.

The effect of age on aldosterone

excretion is not kn0i\!1l., but if it declines with

15

advancing years as does the excretion of the other
adrenal hormones--17-hydroxycorticoids and 17ketosteroids--the difference between the two groups
would be even greater.
SbB noticed that WbBD renal disease was a

secondary complication of essential hypertension,
the mean value of aldosterone excret j~on was higher,
even though the

iD~ividual

normal limits.

But, if the hypertension were due to

values were still within

primary renal disease, the aldosterone excretion values
were beyond normal range.
In addition to studying the physiologic effects
of aldosterone, Genest studied its relationship to
another normally occurring steroid, pregnanetriol.
(Pregnane 3a, 17a, 20a-triol)

This steroid is derived

mainly from prossesterone after 17-hydroxylat iOD..

Sev-

eral authors (40, 41) feel that progesterone is an
aldosteroD.e antagonist because it inhibits the sodium
retaining effect of aldosterone.

Therefore, in

h~rper

tensives one might expect tb.G pregnanetriol values to
be decreased.

Genest found a highly significant

decrease (p is less than 0.001) in average pregnanetriol excretion values for essential, renal, and
malignant hypertension patients as compared with normal subjects.

Similar results were obtained by

Bongiovanni and Eberle

(42)

16

The ratio of pregnanetriol to aldosterone has
been proposed by Genest as an even more sensitive
index of cardiovascular disease.

This is true, he

feels, whether there is an absolute increase in
aldosterone, or a relative increase over a decreased
progesterone.

This ratio

all three groups of

hypertensive patients is below the lo\ver lim.its of
normal range in ninety-two per cent of all patients
studied in this regard.
Since the excretion of pregnanetriol is seemingly affected by the presence of b,)Tpertension, one
:ni,:;;ht expect that other steroi::,! val ues would also
be affected.
ence in

tb~

However, Genest has found no differmean excretion of cortisol, cortisone,

and their tetrahydro derivati\Tes, etiocholanolone,
and the tetrahydro derivative of l'7-hydroxyl, 11desoxycorticosterone in patients with hypertensi.on-essential, renal, or malignant--and normal subjects.
The higher tharl usual excretion rates in hypertensive patients with associated renal disease seem
to indicate a possible renal-adrenal interulay in
this disease.

This uossibility has been variously

considered in the medical literature since 1934,
when Goldblatt and his colleagues uroduced hypertension

1'7

experimentally in animals by clamp
(43)

arter~51.

the renal

Their findings, and later work by

Houssay and Fasciolo of Buenos Aires, suggested that
a h1.1IDOral substance might be responsible for such an
elevation.

This substance was later isolated and

found to be renin, an enzyme

ch reacted on a sub-

strate in nlasma to nroduce a vasoactive substance.
~

l

to note that in 1898, Tigerstedt

(It is interest

and Bergman of Stockhold first demonstrated the nres~

L

ence of a humeral substance in the kidney.

This sub-

stance had remained dormant for thirty-six years until
Goldblatt attempted his classical experiment.)
This vasoactive substance was named variously
hypertensin and angiotonino

To avoid this confusion

in names, the name angiotensin I has been accepted
for this substrate.
peptide.

(44)

Angiotensin I is a poly-

A converting enzyme, also present in the

blood, breaks off two terminal amino acids to form
angiotensin II--an extremely potent octapeptide
vasoconstrictor.

This substance bas been shown to

be ten times as vasoconstrictive as I-epinephrine.

(45)
Cl:he exact nature of this renal-adrenal interplay
has not yet been completely elucidated.

However, it

has been shown (46, 47) that renin infusion in dogs

18

producing experimental hypertension, will increase
the rate of aldosterone secretion.

Carpenter, Davis,

and
Avers
have shown that the infusion of renin into
"
hypophysectomized-nephrectomized dogs will increase
not only aldosterone, but also corticosterone.

Like-

wise, the infusion of synthetic angiotensin II into
similar dogs has been shown to increase both of these
steroids.

In fact, with doses of angiotensin II too

small to elicit a blood pressure response, physiologically significant increases in aldosterone secretion were occasionally observed.

Whereas

dogs

vilith benign hypertension the kidney renin content was
only slightly increased and aldosterone secretion was
within normal limits, in dogs with malignant hypertension, there was a ten-fold increase in renin content of the kidneys and aldosterone output was markedly
increased.
Hardy and his colleagues report the case of a
fourteen year old girl with marked hypertension associatedwith renal artery muscular hypertroDhy.

An

adrenal vein blood sample prior to nephrectomy (which
abolished the

h~fPertension)

showed a markedly elevated

aldosterone content which was statistically significant as compared with that of nonhypertensive patients
undergoing laparotomy.

Postoperatively, the urinary

19

aldosterone was less than half of the value obtained
preoperatively.

They hYDothesize that the renal

lSCDemla ln +-,.
uTI1S case was res
•

1

•

•

sible for the pro-

duct ion of the increased aldosterone levels via a
renin-angiotensin type mechanism.
Genest has also studied extensively the renaladrenal relationships.

(33, 49)

His experiments

consisted of acute and long-term intravenous infusi:J s of synthetic angiotensin, which is identical
to that isolated from oxen, except that the aspartic
acid is replaced by asparagine in the synthetic
material.

In these experiments he studied urine

volum.e, sodium and potassium excretion, glomerular
filtration rate as approximately measured by creatinine clearance, urinary aldosterone, cortisol,
cortisone, and their tetrah;ydro derivatives, in both
normotensive and essential hypertensive individuals
maintained on fixecl sodium and potassium intakes.
His results are summarized below.
I.

Effects of Angiotensin on Urinary
lytes and Creatinine Clearance

ectro-

(An~iotensin

administered at rates to produce an increase
of ei

teen to thirty millimeters of mercury

diastolic pressure above control levels)
20

A.

Results in Normal Subjects
1.

rked sodiu.m retention but with
decrease in both sodium and potassium
excretioYl.

2.

Decrease in urinary sodilJJTI potassium
rat io.

3.

Creatinine clearance variable.
the decrease

(Thus

sodj.um and T)otassium

excretion can occur without change in
glomerular filtration rate.)
B.

Results in
1.

Hyperten~3ive

Subjects

TiHarked sod ium excretion but with
increase in both sodium and potassium
excretion.

2.

Increase inLJ.rinary sodium potassium
ratio.
Increase in creatinine clearance.
few patients to be too signific

II.

(Too
.)

Effects of Angiotensin on Aldosterone and
Otber Corticosteriods.

(Angiotensin admin-

istered at rates to increase diastolic pressure fifteen to thirty-five millimeters of
rilercury above control levels.)
A.

Results in Normal Sub;iects

21

Two and one-half to eleven-fold increase

1.

in urinary aldosterone.
Parallel rise in aldosterone's reduced

2.

metabolite, tetrahydroaldosterone.

3.

In two of four -patients, a two to threefold rise in urirlary cortisol ane] tetrahydrocortisone.

(A rise of this magni-

tude is small in terms of physiologic
si

ificance in comparison to the rise

of aldosterone.)
It is interesting that in two cases where ang10tens

was infused at low levels where the effect was

still subhypertensive, there was a signi
of aldosteronuria.

cant degree

This appears to indicate the great

sensitivity of the aldosterone response to angiotensin.
Control infusions of five per cent glucose, epinephrine,
norepinephrine, and phenylephrine were administered to
these natients to see if the increased urinary aldosterone was
experiment.

,

lJ

1

ne result of the

In all cases exc

level did not undergo any
one instance
rise, but t

stre~:s

th
c

Sl

of the

ion

one, the aldosterone
ificant change. (In

phenylephri~e,

there was a small

was quite small in comparison to that

obtained during the infusion of angiotensin.)
22

Venning

(50) has shown an incrsase in urinary aldosterone
emot i onal stres s s 1 t ua t j ons.

duri

'T'he se exper1-

ments show that th1s increase 1n aldosterone in such
s1tuat1ons is not med1ated through catecholamines.

B.

Results 1n Ben1gn Hypertens1ve Patients
1.

Increase 1n urinary aldosterone.

These stud1es g1ve strong clin1cal support to
the renal-adrenal hypothesis and seem to correlate
well with the experimental studies of Tobian (51)
which link the granulations of the renal juxtaomerular cells to the adrenal zona glome
sodill.m re

lation.

omerulosa,

zO::Ja

osa and

He feels that the w1dth of the
ch secretes aldosterone, thB

gran1Jlarity of the renal juxtaglomeru.lar cells,

'"' '
DrOuao

ch

secrete renin, and thB renin content of the

kidney vary in parallel.

They increase In reSDonse

to low sodium intake, or high renal art

·pressure

such as seen in cases of hypertension and after administration of renin or desoxycorticosterone.
The angiotensin studies of Genest do not solve
all problems, however.

In particular they do not

explain why the increased aldosterone levels during
angiotensin 1nfusions in normal patients are accomDanied by marked sodium restriction and lowering of
the urinary sodium potassium ratio; whereas in patients

23

with hypertension, these same aldosterone increases
are accompanied by marked decreases in the urinary
sodium potassium ratio.

st a

rrhis appears to

basic difference between normal subjects and hypertensive subjects in response to angiotensin.
Selye, (23) in 1942, was tbe first to experimentally produce nephrosclerosis t
desoxycorticosterone acetate.

ougb the use of

s first experiments

were in chicks, but later similar findings were obtained
in the dog, rat, and monkey.

In 1943 he repeated his

experiments in rats, and also dete

d" that thi.s

experimentally induced renal disease would be accompanied by a rise in blood nressure and structural
changes in the systemic blood vessels such as those
seen. in the malignant hypertensive patient.
that this was particularly pronounced

~hen

He noted
the rats

were kept on a higb sodium chloride diet.
s presumptive evidence of the effect of a
mineral corticoid has been repe~ted using aldosterone by Gross.

(55)

He found that aldosterone, if

given in relatively higber amounts than DOCA, WOl}ld
nroduce a comparable increase in blood pressure in
rats.

However, it did not produce the severe renal

lesions which Selye and Gross both observed with
24

DOCA.

This, then, is strong eXDerimental proof of

the effect of aldosterone in an experimental animal.
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Evidence ]\Jot Substantiating This Hypothesis
In a suO.iect whi.ch is exceedingly complex, and
in which there are many different factors occurring,
it is inevitable that there should not be unanimity
of opinion between various authors.

This is cer-

tainly true of this field.
Laragh (53) and his group in 1960 completed a
study of the secretion of aldosterone in hypertension.
His method of analyzing the aldosterone content was
entirely different from that of Genest.

In this

methDd he utilized the technique of radioactive isotope dilution.

This involved the injection of a

tracer of tritium labeled aldosterone, and the determination of the specific activity of its

m~tab01ite,

tetrahydroaldosterone in the subsequent twenty-four
hour urine.

The difference between the specific

activity of the injected tracer and that of the urinary metabolite is a measure of the endogenous contribution.

This permits estimation of the actual daily

secretion of aldosterone, thus obviat

, he feels,

the inherent diff.icul ty in studies which have been
based on mEasurement of the small fraction of aldosterone excreted unchanged in the urine.

By this

technique normal subjects produce one hundred-fifty
26

to tl'xee hundred-fifty lDlcrograms of aldosterone per
day, and this value may rise to one thousand micrograms per day with sodium deprivation.

However, feed-

ing of excess sodium can suppress the normal a160sterone secretion to as low as fifty

crograms per

day.
In this study he classifies hypertensives in
three groups--( 1) primary hypertension, whicJ'l represents patients with benign essential hypertension,
(2) advanced hypertension, which includes those
patients with either nitrogen retention or retinal
hemorrb.ages, and (3) malignant hypertension, il1Nhich
the patients had papilledema.

He found that in patients

with benign hypertension, the rate of aldosterone
secretion was normal.
res

In addition, these patients

ed normally to sodium depreivation by increas-

ing the aldosterone secretion.

However,

also fmJ.nd

that in patients 'lvith primary hypertension, as in nors, increased aldosterone secretion is not necessary for normal sodium conservation.

In addition,

both of these groups showed that the Dlasma potassium,
or the state of potassium

balanc~

lus to aldosterone secretion.

is an important stimu-

This might account for

the increased excretion ascribed to sodium or volume
changes in other studies.
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In contrast to patients with benign h;ypertenE.iion,
those 'vvith malignant hypertension shovved defir1ite
increases in the aldosterone secretion rate.
\Tcl.l1}8S

d from six hundred to ten thousand micro-

grams per day.

At autop

, the adrenal

patients were at or above the upper 1
Thus, these patients d

in we

These

B.nds of these
its of normal

fer from patients

with primary aldosteronism not only in their clinical
features, but also in that in no instance has an adrenal adenoma been discovered.

These patients further

differed from those with benign hypertenf3ion in that
var

tions in the sodium intake did not modify the

aldosterone secretion rate.
jects as well as

However, in these sub-

normals, the aldosterone secretion

rate was related to potassium balance.
In addition to these studies,

measured

the aldosterone secretion rates of patients with Conn's
syndrome.

In these cases, aldosterone values ranged

from five hundred ten to sixteen hundred ninety micrograms per day.

'llhus, in both malignant hypertension

and primary aldosteronism were excessive
obtained.

high value s

Laragh concludes that this hypersecretion

of aldosterone might be a secondary or a cOllcomi tant
uhenomenon.

However, the possibility that aldosterone

might be of causal significance cannot be excluded.
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ThB most damaging cr

icism of the work of Genest

was written by Cope (54) in 1962.

He accepts tbB fact

as stated by Genest that subjects with essential or
t hypertension have a tendency to excrete sig-

mali

nificantly more aldosterone than do normal subjects.
However, he cautions aga

t drawing the conclusion

from these observations that there is necessarily any
etiological relationship between the two.
He hypothesizes several Dossible exnlanations.
fj~here

might be an alteration in renal physiology in

patients with hypertension, whereby aldosterone is
excreted more readily from the blood into t.he urine,
for vvith Genest I s techniques, the relationship between
blood levels and urinary excretion is unknown.
he hypothesi",es, there m
to which aldosterone

be a change

Or,

the extent

bound to a plasma protein, thus

producing a similar situation.

Although methods are

not yet available to estimate the excessively small
concentration of aldosterone found in plasma, and thus
answer these questions, the newly available isotopic
labeled aldosterone has made possible t
of aldosterone secretion rates.
was atte

measurement

Such a measurement

ed by Laragh and the re suIt 8 reT)orted earlier

in this paper.

Cope has repeated these studies.

The

isotope dilution effect makes it possible to estimate
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the total quantity of aldosterone metabolites in the
ur

e, even if many of them are unknown

nature.

This study, in contrast to the one of Laragh,
took cognizance of the fact that patients with severe
renal impairment have a delayed renal excretion of the
labeled aldosterone.

trit

This delayed renal excre-

tion provides opportllnities for proportionately larger
el

ination bv non-renal routes (ie. feces), in which

the radioactive metabolite cannot be detected.

To

correct for this fact, a mathematical formula was
devised and used

i~

his series.

Cope found that for l10rmotensive patients, the
rate of aldosterone secretion was sixty-two to two
hundred seventy-five micrograms per day, with a mean
secretion rate of one hundred forty-three micrograms
per day.

Por hypertensive patients of mixed etiology,

the rates varied from thirty-one to eight hundred
thirt,y-t';No micrograms per day , with a mean va
two hundred twenty-seven micrograms per day.
he feels that the wide scatter of VallJeS (e

of
However,
cases

above tvvo hundred, five below sixty) make the mean
value of little significance.

Thus, although in some

cases the aldosterone secretion rates are above normal,
the series also contains those with rates below normal.
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subdividin~

After

his cases accordi

sis, he finds that of seven cases

to patho.h essential

hypertension, the rates varied from fifty-three to
one hundred sixty-three micrograms DeJ::' day, vvith a
mean value of one h1L."1dred seven micrograms per day.
These fincH

s are in agreement with Laragh, in that

thB aldosterone secretion rates are not raised in

" 1 h_yper t enS10n.
"
essen t 1a

Of nine patients with a

normal pyelogram, the mean secretion rate was two
hundred thirty-five microgram.s per cJay ,I.vi th a range
of forty-t'l'lO to eight hundred thirty-tvlTo micrograms
per day.

~or

nine patients with abnormal pyelo

mean secretion rate was one hundred eight;y-six
micrograms per day, with a range of thirty-one to
foUl: hundred ninety-eight micrograms per day.

In

view of this wide scatter, the difference is of no
significance.

Of four patient,s with malignant

hypertension, two had high secretion rates, while
two were subnormal.

Thtls, very high secretion rates

are by no means invariable in malignant hypertension.
In addition, his study included control patients
who did not have hypertension, b-u.twere ill in various ways.
hype

It is known that many patients with severe

ension are ill in various ways other than \fi}ith

hypertension.

ThUS, it is desirable to compare
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hypertensive subjects with other ill persons who
differ essentially only in that they are normotensive.
None of these ill normotensive patients had fever or
any malignant disease, and in none was there any detectable degree of sodium depletion due to disease of
natriuretic drugs.

In these control patients the

range of secretion was found to be fifty-six to six
hundred four micrograms per day, vIi th a mean value of
two hundred nine micrograms DeI' day.
refore, that tbBre is a

de

It is seen,
e of correla-

tion between the secretion rates of aldosterone in
these two groups.
From these extensive studies Cope concluded that
a raised aldosterone secretion rate will be encountered in hypertensive sub,j ects in about one-third of
the cases.

The range of values is much greater than

that seen in normals.

But, in comparison to otbBr

ill normotensive patients, no detectable d

ferences

can be seen--neither ln ranse of values or mean
secretion

e.

From these conclusions Cope makes three generalizations:
1.

Patients

th uncomplicated essential

hypertension have aldosterone secretion rates within
normal range.
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2.

Patients with malignant

h~rpertension

may

have greatly elevated aldosterone secretion rates,
but do not always.

3.

Hypertensive patients vJith an abnormal

nyelogram are no more likely to show raised aldoh a normal

sterone secretion rates than those
pyelogram.

Thus, these conclusions suggest that the factors
ne whe

these studies are not the ones wbich deterer aldosterone secretion is raised or not.

It appears, thBrefore, that some determining factor
or factors must be acting independent

of the etio-

logi.cal classificat ion of the hypertensive condit ion.
He feels the nature of such factors can only be speculated upon.

However, these studies seem to indicate

that many t:v-pes of metabolic derangement can increase
aldosterone secretion, just as many types of stress
can increase cortisol production.

And, since the

comparison of aldosterone secretion in normotensive
metabolic disorders to hypertensives is so similar,
seems suggestive that at least some of the etiological factors acting in the normotensive group are
also operating in the hypertensive group. Thus, some
of the aldosterone overproduction seen
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hypertensives

might be incidental manifestations of associated
metabolic disturbances.
He states, "it seems most improbable that a
mild chronic overproduction of aldosterone is concerned in the pathogenesis of essential hYPertension
as suggested by Genest, for neither Laragh nor we have
found any evidence of raised aldosterone production
in essential hypertens ion.

Iv10reover, Genest has

shown that angiotensin acts as a stimulant to aldosterone production even in doses too small to uroduce detectable hypertension.

This claim, therefore,

suggests that raised aldosterone secretion should be
a sensitive indicator of circulating angiotensin-more sensitive indeed than the blood pressure itself.1I
(5 Lj-)

This is very doubtful, and can only be det er-

mined when plasma angiotensin levels can be easily
ascertained.

There is no reason to think that angio-

tensin is the only stimulus to aldosterone production.
Genest has also suggested that the aldosterone
levels may be only intermittently raised in hypertensive studies, thus explaining why spot tests
of secretion rate may not reveal

tb~s

rise.

Cope

feels there is little evidence to support this
tion.

assujJ~p

He also presents additional evidence against

the role of aldosterone in the causation of hypertension.
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He relates that chlorothiazide and other like
natriuretics often stimulate increases in aldosterone excretion as sodium is lost.

However, in

these cases, the blood pressure falls rather than
rises.
There are other factors which seem to be unfavorable to the basic asslJ.mption of the importance
of the role of aldosterone in the pathogenesis of
hypertension.

It is well known that the highest

values of aldosterone secretion occur in conditions
other than hypertension.

Dr. Ralph Peterson has

found values up to three thousand micrograms per day
in the states of cirrhosis and heart failure.

Luetscher

(55) and his group confirm these findings of very
~igh

aldosterone levels in conditions of ascites,

rena}, and hepatic failure.

Gross (56) points out

that one of the most famous examples of increased
aldosterone secretion is in a normal pregnancy.

This

is not due to an increased production of aldosterone,
but a changed metabolism.

And, in normal pregnancy,

the blood pressure remains normal.

However, in

toxemia of pregnancy, when the blood pressure is
elevated, the same values are seen as in a normal
pregnancy.
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The well-taught fact that aldosterone is independent of pituitary control cannot be stated too
dogmatically.

Several

author~

including Venning

(57) and her colleagues, have found significant
increases in the excretion of aldosterone after administration of ACTIL

Venning's work suggested that ACTH

may act synergistically with a specific aldosterone
stimulating factor to enhance the secretion of aldosterone.

These observations

sug~est

caution in inter-

preting aldosterone secretion rates in stressful situations.

This effect is much less important than in

the synthesis of glucocorticoids.
Dawson

(58) and his group attack

blem from a different standpoint.

tb~

basic pro-

He reasons that if

aldosterone hypersecretion does influence malignant
hypertension, it m"'ght be expected that an
tion of aldosterone secretion should lower the blood
nressure in these patients.

Such an inhibition can

be achieved by the administration of SU

4885, which

blocks the II-hydroxylation step in the biosynthesis.
The use of this drug was first renorted by Jenkins
ro' and-...b"
( )))
~lS group.

In hi

dosages this causes a

seneral suppression of steroid biosynt

sis.

In addi-

tion, the metabolic excretion product, tetrahydrodesoxycorticosterone, also having mineral corticoid
properties, is similarly blocked.

In this study a thirty-seven year old male with
malignant hypertension was treated with f;U 4885 and
~rednisone.

Prednisone was to act as a replacement

for the glocucorticoids suopressed.

In this patient,

the institution of therapy was associated with an
increased rate of urine sodium and chloride excretion, a fall in serum sodium, a',d a
potassium.

se in serum

the treatment the aldosterone excre-

Dur

11 to minimally detectable rates.

tion

ACTH test

performed during the treatment showed marked adrenal
irment w

very low cortisol levels.

However,

there was no significant change in the patient's blood
pressure nor any improvement in his symptoms.

These

studies suggest that aldosterone hypersecretion is not
the cause of, or the primary event in the pathogenesis
of malignant hypertension.
Hollander and Chabonian (60) exp
aldosterone found in malignant hype
method.

n t

increased

ension Ilia another

They have found that patients with primary

Idoste:::'onism and patients with malignant hypertension have s

icant increases in total exchangeable
:zr

sod.1u..1J, as determined by the 8)/04 space.

Normal con-

troIs and patients with essential hypertension dtd not
have thBse findin

, although the pattent with benign
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hypertension in congestive failure did.

Also, these

investigators noticed that the total exchangeable
potas lum space was decreased severely in patients
with prlmary eldosteronism, but on

slightly decreased

in patients with malignant hypertension.

They pos-

tulate that the increase in sodium and extracellular
fluid volume may be manifestations of a state of
precoIJgestive heart failure, and this state may be
responsible for the increased aldosterone excretion
seen.
Not all lnvestigators have been able to nrodu6e
hypertension in experlmental situatlowby thE administration of aldosterone.

It ls lnteresting to note

that In patlents with Addison's disease, treatment
wlth large doses of aldosterone normalizes the blood
pressure, but does not cause hYTJertension.

Gross (61)

obserV'2d hynertension in rats sensitized by unilateral
nephrectomy only when he injected five hundred mlcrograms of dl-aldosterone dally for four weeks.

However,

Gaunt noted no slgns of hypertension in intact rats
when administering the same dose over seven months.
In man, Thorn (62) has found that a dose of six thousand micrograms of aldosterone daily provokes a rise
blood pressure of only ten to twenty-two millimeters of mercury.
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warter (63) and his co-workers feel that aldosterone may provoke hypertension only in the presence
of renal lesions.

They suggest, also, that there

may be great differences in sensitivity of the renal
tublJleEJ to aldosterone in hypertensive pa tient s.

They

cite the example of one hypertensive pa-Gient in which
the administration of one thousand micrograms of aldosterone for three days had no noticeable effect on
either blood pressure or electrolyte balance.
Perhaps the most s

ificant evidence against

the role of aldosterone in the pathogenesis of hypertension can be found in the report of Bar~ter (64)
in 1962.

In this .report he described three cases of

a new clinical syndrome, hyperaldosteronism and hypokalemic alkalosis viithout hypertension.

CJ:1hese patients

were examined because of varied, nonspecific reasons,
and were found to have four important aspectf3 in comn~on.

-Each had a hypokalemic alkalosis vvith potas-

sium values of 1.2 -2.3 mEq/L.

Each had an elevated

aldosterone level--up to seven hlJ_ndred fifty mjcrograms Der day, but none of these patients had elevated
blood pressures after many readings and an extensive
study.

Because of the hyperaldosteronism, each patient

had a kidney biopsy which revealed a unique lesion of
the juxtaglomerular aI)paratus.
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This lesion consisted

of hypertrophy of the juxtaglornerular apparatue, which,
from fixed preparations appeared to comprise four stages:
1.

hypertrophy of tl1e macula densa

2.

thickening of the juxtaglomerular cells with

hyperplasia of the juxtaglomerular apparatus

3.

hyperchromatism of the vascular wall of part

of the glomerulus
4.

ai!t0phy of the glomerulus

II'he de"veloJ)ment of h;vpo}-;:alemia vvas

associ,:~.ted

with urinary loss of potassium in excess of intake.
This loss was decreased but not prevented by restriction of sod ium intake.

It was also nrevented
bv
the
"_
u

infusion of serum albumin (which decreased the urinary sodium to zero) and aldosterone antagonists.
The blood pressure remained normal, even when the
extravascular snaces were expanded with albmnin, so
the absence of hYTlsrtensioIl cannot be attrib"Llted to
hypovol

a.

The lesions of the juxtaglomerular apparatus
su::;gest a l:t,ypersecretion of renin which should lead
to hypertension.
bioass
resembl

In addition, these patients on

showed increased amounts of a pressor agent
angiotensin in the sermIl.

There

lS

little

reason to believe that aldosteronism or the resulting
potassium depletion produced the renal lesion, since
40

lesions have not been found 1n patients with

simi

kidneys

primary or secondary aldosteronism, or in t
of potassium-depleted rats.
of aldosterone or

In fact, administration

meA to rats on average or 11.igh

sodium diets causes a decrease in the prominence of
omerular apparatus, and a decrease in the

the ,luxt

-renin content of the kidney.

It is

ssible also that

the aldosteronism and the j1Lxtaglomerular apparatus
lesion are both results of an lli'1identified
cause.

coml:~on

However, it is more likely that the renal

lesion should have

d

to the adrenalone.

Although available evidence does not make a
def

ite explanation possible in this syndrome,

Bartter has proposed a working hypothesis.

In nor-

mal patients, he feels that angiotensin II, after
its production via renin, has three functions:

(1)

a direct effect of blood pressure, (2) retention of
sodium-via the kidney, and (3) stimulation of aldosterone secretion.
pre s ,sure or

Normally, some function of blood

se acts asa negative feedback to inhi-

bit renin production.

However, he suggests that in

these patients, for reasons unknown, there is a primary impairment in the vascular response to angiotensin.

This results in a decreased in11ibition of

renin production, therefore increased production of
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, and an increase

iotensin I, angiotens

renin,

in aldosterone secretion.

He hypothesL'>es that in

tbese cases, even though the angiotensin II is Unable
to

duce hypertension due to the primary defect, it

might still stimulate the adrenal cortex to tbB overnroduction of aldosterone.
Cope (54) attempts to explain raised aldosterone
secretions encountered in some hypertensive subjects
by

nostulatin~

that there must be some other aspect

of illness rather than the hypertension which is the
determin

g factor.

He states that Laragh (53) and

his group had observed that there was no apparent
relation between the

hei~ht

of t

blood pressure and

the increased secretion rates of aldosterone which he
found.

However, Laragh cUd notice that in

1,

the hypersecretion of aldosterone was more ilnpresE3ive
in the seriously ill patients.
have noted similar phenomena.

Other investigators
Venning (65) noted an

increased urinary excretion of aldosterone and tetrahydroaldosterone in hypertensives when the
condition was deteriorating.

general

Llaurado (60) has shown

an increased urinary excretion of aldosterone due to
a non-specific disturbance such as a surgical operation.

Laragh (61) feels also that increased aldoster-

one secretion may be seen in essential hypertension
42

patients as renal or caEliac complications develop.
Cope agrees with this general thesis, and feels when
increased aldosterone secretion occurs in essential
hypertension, it is probably due to a complicating
factor.

He feels this is probably also true in

malignant hypertension.
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BUlVIMARY

1.

The scope of the problem of hypertension is
discussed, and a classification stated.

2.

The physiologic and chemical properties of
aldosterone are presented.

3.

Presumptive evidences for the relationship of
aldosterone to hypertension are Etated.

4.

The body of the thesis is used to present
affirmative and negative evidence in regard to
a basic hypothesis--that aldosteron.e is an etiologic agent in hypertension.

Included in this

evidence are views of various investigators
as to aldosterone urinary excretion studies,
experimental production of hypertension, and a
new syndrome of hyperaldosteronism and hypokalemic alkalosis without h;ypertension.
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It is difficult to reconcile the differing
results obtained by separate investigators in studying the same aspects of a given problem, unless one
considers differences in techniques and methods used.
The major differences in opinion as to the urinary
excretion of aldosterone as presented in this thesis
are represented by Genest and Garst on one hand, and
Laragh and Cope on the other.
preted in this manner.

These must be inter-

Whereas the former investi-

gators used a paper chromatographic method in their
findings of an increased urinary excretion of aldosterone in hypertensives (and implied from this an
increased secretion), the latter men used a radioactive isotonic dilution technique in their finding
of no increased secretion of aldosterone in hypertension.

Although it is not possible to be dogmatic

on this point, is appears most logical that the
radioactive isotopic dilution method would be the
more accurate.
It would be false for one to say that there is
not a large body of presumptive evidence which tends
to associate increased aldosterone levels with essential hypertension.

However, this presumptive evidence
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of association is m.uch different from true concrete
evidence of causation.

The recently described syn-

drome of hyperaldosteronis:n without hypertension does
much in negating such presumptive evidence.
~or

these reasons, this author must, in conclu-

sion, agree with Cope, that hyperaldosteronism is
not a causative factor in either essential, renal,
or malignant hypertension, but its frequent presence
in such cases is probably due to secondary complicating factors, the exact nature of which is not
yet known.
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I would like to express my appreciation to Dr. R. Lo Grissom for his
helpful comments and sWsfl;estions in the
preparation of this

thesis~
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